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Abstract
Objective: Panax ginseng C.A. Meyer is a well-known medicinal herb in North America and Europe. The pur-
pose of this study was to investigate the association between ginseng intake and mortality among members of
the Korean population.
Methods: We followed 6282 subjects who were 55 years of age or older in March 1985 until December 31, 2003.
The Cox proportional hazard regression model was used to evaluate effects of ginseng intake on mortality.
Results: Adjusting for age, education, occupation, drinking, smoking, self-reported chronic disease, body mass
index, and blood pressure, all-cause mortality for male ginseng users was significantly lower than that for male
nonusers (Hazard ratio [HR]  0.90; 95% confidence interval [CI], 0.81–0.99). However, such an association was
not observed in women (HR  1.03; 95% CI, 0.94–1.13). Cancer-specific mortality was lower in female ginseng
users than female nonusers after adjustment of relevant covariates (HR  0.80; 95% CI, 0.60–1.08). Compared
to nonusers, the HR for cancer-specific mortality in women was 0.84 in infrequent users (95% CI, 0.62–1.15)
and 0.61 in frequent users (95% CI, 0.32–1.14) (p for trend, 0.09), which is not statistically significant. The can-
cer-specific mortality was not associated with ginseng intake in male subjects (HR  0.95; 95% CI, 0.76–1.20).
Mortality caused by cardiovascular diseases was not related to ginseng intake in both men and women.
Conclusion: The 18.8-year progressive cohort study showed that ginseng intake decreased all-cause mortality
in older males, but such life prolongation effect was not shown in women.
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Introduction
Ginseng, a deciduous perennial plant, has been proposedas a medicinal herb to enhance stamina and cure many
diseases in Asia, especially Korea and China, for thousands
of years.1 In the western world, ginseng has been sold in var-
ious types of food supplement at health food stores, drug-
stores, and superstores.2 Ginseng has been among the top
ten selling herbal supplements in the United States over the
past decade.3
Among 13 species of ginseng known so far,1 Panax gin-
seng C.A. Meyer (Korean ginseng) and P. quinquefolium L.
(American ginseng) are highly valued and most utilized
across the world. Modern therapeutic claims for P. ginseng
refer to vitality, immune function, cancer, cardiovascular
disease, cognitive and physical performance, and sexual
function.4 The efficacy of ginseng has been studied largely
through animal testing and experimental research,5 but
studies based on randomized clinical trials or population
observation are rare.
With regard to population studies on ginseng, two case-
control studies6,7 and three cohort studies have been re-
ported so far.8–10 Like most in vivo animal studies and in vitro
experimental studies, these population studies examined
mainly the preventive or therapeutic effect of ginseng against
cancer. Although its effect on prolongation of life was de-
scribed in Shen Nong Ben Cao Jing (The Divine Farmer’s Ma-
teria Medica), one of the oldest pharmacopoeias in the
world,11 any association of ginseng intake with mortality
among the general population of a local community has not
been previously reported.
This study examined the relationship between ginseng in-
take and mortality from all causes, cancers, and cardiovas-
cular diseases through a long-term prospective cohort study
in Kangwha county, one of famous ginseng cultivating lands
in Korea.
1Department of Preventive Medicine and Public Health, Kwandong University College of Medicine, Gangneung, Republic of Korea.
2Institute for Health Promotion, 3Department of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei Uni-
versity, Seoul, Republic of Korea.
4Health Insurance Review Agency, Seoul, Republic of Korea.
5Department of Family Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Methods
Study population and location
This study used the data of the Kangwha Cohort
Study.12,13 Among 9378 residents of Kangwha county who
were 55 years or older in February 1985, 6372 subjects (67.9%)
participated in interviews about ginseng use, and measure-
ments of blood pressure and body mass. Those who had no
information on ginseng intake (n  51) at entry or was not
followed up after the initial survey (n  39) were excluded,
and thus the final study population recruited was 6282 (male,
2695; female, 3587). Kangwha county consists of several is-
lands approximately 50 km west from Seoul. Its population
was 71,116 in 199314 and it had one of the areas of cultiva-
tion of P. ginseng C.A. Meyer in Korea.8
Baseline data collection and follow-up
The initial survey for the Kangwha Cohort Study was con-
ducted over a month in March 1985. Each subject was inter-
viewed using a structured questionnaire to collect data on
demographic characteristics: education, occupation, health
conditions at entry, health behaviors, diet, and other factors.
Blood pressure, height, and weight were measured by
trained investigators. For the question “How often do you
take ginseng, including ginseng liquor (any amount)?,” par-
ticipants were asked to choose from “very often, often, oc-
casionally, never.” The study subjects were followed up un-
til December 31, 2003, and thus the maximum period of
follow-up for death was 18.8 years. The total observed per-
son-times was 30,505 person-years.
Outcome assessment
The outcomes of this study are all-cause deaths and cause-
specific deaths. Data on deaths and their causes from Janu-
ary 1, 1992 to December 31, 2003 were obtained from the
Statistics on the Causes of Death of Korea of the Korea Na-
tional Statistical Office. The data from March 1985 to De-
cember 31, 1991 were collected either through calls and vis-
its of trained surveyors twice a year or from records of burial
and death certificates of eup and myeon offices (administra-
tive branch offices of local government in Korea). The In-
ternational Classification of Diseases 10th Revision (ICD-10)
was applied to define the causes of death, which were clas-
sified into cancers (C00-C99) or total cardiovascular diseases
(I00-I99).
Statistical analysis
Ginseng users were grouped into infrequent users (occa-
sionally) and frequent users (very often, often) to examine
the relationship between ginseng intake and mortality more
closely. Sociodemographic characteristics and potential vari-
able factors for infrequent users and frequent users were con-
trolled with ANOVA and Chi-square test. HR and 95% CI,
survival function, and hazard function for ginseng intake
were calculated with the Cox proportional hazard regression
model. The variables adjusted in our study were: age at en-
try (years); education (none, elementary school, middle
school, or higher); occupation (agriculture, other); drinking
(current drinker, non-drinker); smoking (current smoker,
past smoker, never); self-reported chronic disease at entry
(yes, no); body mass index ( 25,  25); and elevated blood
pressure (systolic blood pressure (SBP)  140 or diastolic
blood pressure (DBP)  90, SBP  140 and DBP  90). All
analyses were made by sex separately (Table 1).
Since users who had a disease or health problem at entry
might take ginseng or there would be a lag time until gin-
seng took effect for subjects starting ginseng intake around
study entry, we also implemented a lag time analysis in
which those whose follow-up ended before December 31,
1989 (with less than 4.8 years of follow-up) were excluded
from analysis. In the trend test, nonusers were numbered as
1, infrequent users as 2, and frequent users as 3, and ginseng
intake was set as a continuous variable. We estimated the
survival function and risk function of mortality against gin-
seng intake with adjustment for all variables using the Cox
proportional hazard regression model, and examined how
differently ginseng intake took effect for each follow-up pe-
riod.15 HR, 95% CI, and p-values in this study were all cal-
culated by the two-tail test. The SAS System for Windows v.
9.13 was used for statistical analysis.
Results
Sixty-nine percent of males (1848/2695) and 51% of fe-
males (1832/3587) were ginseng users (infrequent or fre-
quent users). The crude all-cause mortality rate of nonusers,
infrequent, and frequent users was 72.7, 61.6, and 56.3
deaths/1000 person-years in men; and 42.7, 38.1, and 38.9
deaths/1000 person-years in women, respectively. Male gin-
seng users were younger, more educated, and drank more
than nonusers; male infrequent users smoked more and were
more hypertensive than male nonusers or male frequent
users. Female ginseng users were younger, more educated,
but had less alcohol consumption than nonusers; and female
frequent users smoked more but were less hypertensive than
the other two female groups.
Unadjusted HR showed that ginseng intake was signifi-
cantly associated with decreasing all-cause mortality in both
men (HR0.81; 95% CI, 0.74–0.89) and women (HR0.89;
95% CI, 0.81–0.97). After adjustment for age and other vari-
ables, ginseng intake was still significantly associated with
all-cause mortality in men. And the analysis using 4.8 years
lag time for male groups produced the statistically signifi-
cant result of more decreased death risk (HR  0.82) than
when no lag time was applied. But such associations were
not observed in women (Table 2).
Survival function estimates for all-cause mortality were
adjusted for all variables using the Cox proportional hazards
model. Male ginseng users showed a noticeably higher sur-
vival rate pattern than male nonusers from around year 5
(Fig. 1), whereas the survival rate of female ginseng users
was higher than that of female nonusers from years 1 to 14,
with the gap narrowing thereafter (Fig. 2). On the hazard
function curve, all-cause mortality risk of male ginseng users
is lower than male nonusers from around year 5 (mean
monthly hazard function for users vs. nonusers: follow-up 
60 months, 0.0036 vs. 0.0038; follow-up  60 months, 0.0064
vs. 0.0084), but all-cause mortality risk of female ginseng
users is higher than that of female nonusers from around
year 14–15 (mean monthly hazard function for users vs.
nonusers: follow-up  168 months, 0.0023 vs. 0.0029; follow-
up  168 months, 0.0064 vs. 0.0058).
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0.
When male cause of death was analyzed, unadjusted haz-
ard ratio showed that ginseng intake was not associated with
deaths from cancers (HR  0.91; 95% CI, 0.73–1.14) and car-
diovascular diseases (HR  0.95; 95% CI, 0.77–1.17). After
adjusting for age and other variables, male deaths caused by
cancers and cardiovascular diseases had no association with
ginseng intake. The exclusion of deaths during the first 4.8
years insignificantly lowered the hazard ratio of cancer mor-
tality from 0.95 to 0.82.
In women, the unadjusted mortality risk of ginseng users
was insignificantly lower for cancer deaths (HR  0.81; 95%
CI, 0.61–1.09) and cardiovascular disease deaths (HR  0.90;
95% CI, 0.75–1.08) than that of nonusers. After adjustment
for variables for female groups, however, the risk of deaths
from cancers and cardiovascular diseases had no association
with ginseng intake.
When the frequency of ginseng intake was taken into ac-
count for men, unadjusted all-cause mortality risk trended
lower for infrequent users (HR  0.83; 95% CI, 0.76–0.92)
than for frequent users (HR  0.76– 95%; CI, 0.67–0.87) (p for
trend  0.001). In women, all-cause death risk was signifi-
cantly low in infrequent users (HR  0.89; 95% CI, 0.81–0.97)
but insignificantly low in frequent users (HR  0.90; 95% CI,
0.77–1.06) (p for trend  0.02).
After adjusting for age and other potential variables for
men, the hazard ratio was 0.90 for infrequent users and 0.87
for frequent users. With the initial 4.8 years of death ex-
cluded, the hazard ratio of infrequent users was 0.80 (95%
CI, 0.71–0.91), but frequent users did not show a notable dif-
ference. The test for trends showed the risk of male all-cause
mortality decreased significantly with the increasing fre-
quency of ginseng intake regardless of adjustment for vari-
ables (Table 3). In women, after adjustment for variables, the
frequency of ginseng intake had no association with all-cause
mortality.
When the frequency of ginseng intake was further ana-
lyzed by cause of death for male subjects, deaths caused by
cancers and cardiovascular diseases showed no association
with ginseng intake frequency regardless of adjustment for
variables. In the same analysis for female subjects, the un-
adjusted hazard ratio of cancers was 0.85 in infrequent users
(95% CI, 0.63–1.15) and 0.61 in frequent users (95% CI,
0.33–1.14), indicating ginseng intake frequency proportion-
ally lowered mortality risk with a borderline significance (p
for trend  0.09). This trend remained in effect in variables-
adjusted models (p for trend  0.09). Cardiovascular disease
mortality had no association with ginseng intake frequency
regardless of adjustment for variables.
Discussion
From this 18.8-year population-based cohort study, we ob-
served that ginseng intake correlated with significantly re-
duced all-cause mortality risk of elderly males. After ad-
justment for age and other variables, ginseng intake also
showed a weakened but significant correlation with de-
creased mortality risk. The trend test showed that all-cause
mortality risk decreased as ginseng intake was increased. El-
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TABLE 2. ASSOCIATION OF GINSENG INTAKE WITH ALL CAUSES OF DEATH AND DEATHS CAUSED BY CANCERS, 
CARDIOVASCULAR DISEASES, AND UNCLASSIFIED DISEASES IN KANGWHA COHORT STUDY, 1985–2003
Males Females
Nonusers Users Nonusers Users
Deaths HR Deaths HR 95% CI Deaths HR Deaths HR 95% CI
All causes of death (ICD10: A00-Z99)
Age adjusted 650 1.0 1294 0.90 0.82–0.99 994 1.0 984 1.04 0.95–1.13
Multivariate adjusteda 644 1.0 1286 0.89 0.81–0.98 993 1.0 984 1.04 0.95–1.14
Multivariate adjustedb 624 1.0 1265 0.90 0.81–0.99 956 1.0 955 1.03 0.94–1.13
Multivariate adjusted with 438 1.0 884 0.82 0.73–0.92 723 1.0 758 1.05 0.95–1.17
4.8-year lag timeb,c
Cancers (ICD10: C00-C99)
Age adjusted 114 1.0 256 0.93 0.74–1.16 96 1.0 87 0.81 0.61–1.08
Multivariate adjusteda 113 1.0 254 0.96 0.77–1.20 96 1.0 87 0.82 0.61–1.10
Multivariate adjustedb 111 1.0 252 0.95 0.76–1.20 95 1.0 85 0.80 0.60–1.08
Multivariate adjusted with 82 1.0 171 0.82 0.63–1.07 68 1.0 67 0.85 0.61–1.20
4.8-year lag timeb,c
Cardiovascular diseases (ICD 10: I00-I99)
Age adjusted 120 1.0 281 1.03 0.83–1.28 234 1.0 237 0.99 0.82–1.18
Multivariate adjusteda 117 1.0 279 0.98 0.78–1.22 234 1.0 237 0.99 0.82–1.19
Multivariate adjustedb 110 1.0 276 1.01 0.81–1.26 229 1.0 232 0.98 0.81–1.18
Multivariate adjusted with 76 1.0 214 1.06 0.81–1.39 202 1.0 198 0.93 0.76–1.14
4.8-year lag timeb,c
aFor males, adjusted for age at entry (years); education (none, elementary school, middle school, higher); occupation (agriculture, other);
drinking (current drinker, non-drinker); and elevated blood pressure (SBP  140 or DBP  90, SBP  140 and DBP  90). For females; ad-
justed for age at entry (years); education (none, elementary school, middle school, higher); occupation (agriculture, other); drinking (current
drinker, non-drinker); and smoking (current smoker, past smoker, never).
bAdjusted for age at entry, education, occupation, drinking, smoking, chronic disease at entry (ever, never), body mass index (BMI  25.0,
BMI  25), and elevated blood pressure (SBP  140 or DBP  90, SBP  140 and DBP  90).
cAnalysis was done excluding subjects who had been followed-up by December 31, 1989 (less than 4.8 years follow-up).
HR, hazard ratio; CI, confidence interval.
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FIG. 1. Survival function estimates curve for all causes of mortality by ginseng intake among males, Kangwha Cohort
Study, 1985–2003.
FIG. 2. Survival function estimates curve for all causes of mortality by ginseng intake among females, Kangwha Cohort
Study, 1985–2003.
derly females also showed a significant association between
ginseng intake and decreased mortality risk before adjust-
ment for age and variables, but no association was shown
after adjustment.
In our analysis by cause of death, ginseng intake was not
significantly associated with deaths due to cancers in men
or women. But it lowered the risk of mortality from cancers
in women, with a relationship between greater ginseng in-
take and lower risk approaching significance. An earlier
case-control study6,7 and cohort study8 by Yun and Choi re-
ported ginseng intake had a strong preventive effect on var-
ious human cancers. It is not evident why these two former
studies and this study, both on Koreans, reported differing
results. Since the control group in the case-control study by
Yun and Choi consisted of patients who had been admitted
to the same hospital as cancer patients, their ginseng intake
might have been higher than that of the general population.10
And the study group in their cohort study was a mean 12
years younger than in this study, which can be another pos-
sible cause of difference. But when we analyzed subjects by
stratified age, the effect of ginseng intake was not more ev-
ident at younger ages. For ginseng users under 65 years of
age the adjusted hazard ratio of all-cause mortality was 0.95
(95% CI, 0.70–1.30) in men and 0.80 (95% CI, 0.54–1.18) in
women, whereas for ginseng users 65 years of age or older
it was 0.98 (95% CI, 0.70–1.36) in men and 0.76 (95% CI,
0.48–1.20) in women.
Studies in Chinese populations have reported different re-
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TABLE 3. ASSOCIATION OF GINSENG INTAKE FREQUENCY WITH ALL CAUSES OF DEATH AND DEATHS CAUSED BY CANCERS,
CARDIOVASCULAR DISEASES, AND UNCLASSIFIED DISEASES IN KANGWHA COHORT STUDY, 1985–2003
Nonusers Infrequent users Frequent users
Deaths HR Deaths HR 95% CI Deaths HR 95% CI P for trendd
Males
All causes of death (ICD10: A00-Z99)
Age adjusted 650 1.0 931 0.91 0.82–1.01 363 0.87 0.76–0.99 0.025
Multivariate adjusteda 644 1.0 926 0.90 0.82–1.00 360 0.87 0.77–1.00 0.027
Multivariate adjustedb 624 1.0 911 0.90 0.82–1.00 354 0.87 0.76–1.00 0.030
Multivariate adjusted with 438 1.0 619 0.80 0.71–0.91 265 0.87 0.74–1.01 0.028
4.8-year lag timeb,c
Cancers (ICD10: C00-C99)
Age adjusted 114 1.0 178 0.92 0.72–1.16 78 0.95 0.71–1.26 0.657
Multivariate adjusteda 113 1.0 177 0.95 0.75–1.20 77 1.00 0.75–1.34 0.955
Multivariate adjustedb 111 1.0 175 0.94 0.74–1.19 77 1.00 0.74–1.35 0.941
Multivariate adjusted with 82 1.0 119 0.81 0.61–1.07 52 0.84 0.59–1.20 0.279
4.8-year lag timeb,c
Cardiovascular diseases (ICD 10: I00-I99)
Age adjusted 120 1.0 202 1.04 0.83–1.31 79 0.99 0.75–1.32 0.982
Multivariate adjusteda 117 1.0 200 0.99 0.79–1.25 79 0.93 0.70–1.25 0.656
Multivariate adjustedb 110 1.0 197 1.02 0.81–1.30 79 0.97 0.72–1.31 0.882
Multivariate adjusted with 76 1.0 148 1.04 0.78–1.37 66 1.12 0.80–1.57 0.508
4.8-year lag timeb,c
Women
All causes of death (ICD10: A00-R99, V01-Y89)
Age adjusted 994 1.0 816 1.03 0.94–1.13 168 1.06 0.90–1.25 0.403
Multivariate adjusteda 993 1.0 816 1.04 0.94–1.14 168 1.07 0.90–1.26 0.339
Multivariate adjustedb 956 1.0 794 1.03 0.94–1.13 161 1.03 0.87–1.22 0.524
Multivariate adjusted with 723 1.0 624 1.04 0.94–1.16 134 1.10 0.92–1.33 0.260
4.8-year lag timeb,c
Cancers (ICD10: C00-C99)
Age adjusted 96 1.0 76 0.85 0.63–1.15 11 0.61 0.33–1.14 0.090
Multivariate adjusteda 96 1.0 76 0.86 0.63–1.16 11 0.63 0.34–1.18 0.113
Multivariate adjustedb 95 1.0 74 0.84 0.62–1.15 11 0.61 0.32–1.14 0.085
Multivariate adjusted with 68 1.0 59 0.91 0.64–1.29 8 0.58 0.28–1.21 0.188
4.8-year lag timeb,c
Cardiovascular diseases (ICD 10: I00-I99)
Age adjusted 234 1.0 197 0.98 0.81–1.19 40 1.00 0.71–1.40 0.919
Multivariate adjusteda 234 1.0 197 0.99 0.81–1.19 40 1.01 0.72–1.42 0.983
Multivariate adjustedb 229 1.0 192 0.97 0.80–1.18 40 1.01 0.72–1.42 0.919
Multivariate adjusted with 202 1.0 159 0.90 0.73–1.11 39 1.09 0.77–1.54 0.389
4.8-year lag timeb,c
aFor males, adjusted for age at entry (years); education (none, elementary school, middle school, higher); occupation (agriculture, other);
drinking (current drinker, non-drinker); and elevated blood pressure (SBP  140 or DBP  90, SBP  140 and DBP  90). For females; ad-
justed for age at entry (years); education (none, elementary school, middle school, higher); occupation (agriculture, other); drinking (current
drinker, non-drinker); and smoking (current smoker, past smoker, never).
bAdjusted for age at entry, education, occupation, drinking, smoking, chronic disease at entry (ever, never), body mass index (BMI  25.0,
BMI  25), and elevated blood pressure (SBP  140 or DBP  90, SBP  140 and DBP  90).
cAnalysis was done excluding subjects who had been followed-up by December 31, 1989 (less than 4.8 years follow-up).
dThe trend test was done using nonuser, infrequent user, and frequent user as continuous variables 1, 2, and 3, respectively.
HR, hazard ratio; CI, confidence interval.
sults on the preventive and treatment effect of ginseng in-
take. In the Shanghai Breast Cancer Study9 the mortality rate
of ginseng users among breast cancer patients was signifi-
cantly low, whereas the Shanghai Women’s Health Study10
reported no association between ginseng intake and stom-
ach cancer risks. Based on the varied results of studies on
ginseng intake so far, the effect of ginseng as a non-or-
gan–specific cancer preventive herbal medicine, suggested
by Yun and Choi, cannot be confirmed and further research
is required to examine the preventive effect of ginseng on
cancer.1,6–8, 23
This study supports previous studies that found no rela-
tionship between ginseng intake and cardiovascular disease
risk. A recent systematic review on human clinical trials for
ginseng intake and cardiovascular disease risk factors re-
ported there was no evidence that ginseng intake plays a
positive role in blood pressure, glucose, and lipid profiles.21
In our study, male ginseng users were more hypertensive
than male nonusers, and after adjustment for age, sex, edu-
cation, and BMI, the systolic pressure of male ginseng users
was 3.3 mm Hg higher than that of male nonusers (p 
0.006). Our analysis of ginseng intake and deaths from car-
diovascular disease showed no significant relationship either
based on ginseng intake or intake frequency. Although
American adults with hypertension have been taking gin-
seng recently,22 this study did not show ginseng intake had
a positive effect on blood pressure or deaths from cardio-
vascular disease.23
Deaths from other diseases excluding cancers and cardio-
vascular disease showed similar hazard ratios (age adjusted
HR  0.86; 95% CI, 0.79–0.97) as ginseng intake decreased
the mortality risk of all-cause deaths in men. Also, when the
lag time analysis was taken, the mortality risk of male gin-
seng users for other diseases was statistically significantly
lowered for all-cause deaths (multivariate adjusted HR 
0.76; 95% CI, 0.65–0.88). We cannot present a clear perspec-
tive on why the mortality risk of male ginseng users was
lower for other diseases than for cancers or cardiovascular
diseases. Many in vitro and animal studies have suggested
that the metabolic effects relate to the adaptation of homeo-
static mechanisms resulting from exposure to stress, in-
creased adrenal responsiveness, enhancing immunologic
function, immunostimulatory activity in the aged, and anti-
oxidant activity.4,23 More double-blind randomized clinical
trials and population-based studies would be required for
an accurate conclusion.
There is a possibility that the effect of ginseng intake dif-
fers by sex. The all-cause mortality risk of male ginseng users
was statistically significantly lower, but no such trend was
shown in women. There was no association between cancer
mortality and ginseng intake in men, whereas in the trend
test for female ginseng users the cancer mortality risk de-
creased with a borderline significance as ginseng intake was
increased. From the analysis of all-cause deaths, the efficacy
of ginseng intake emerged in men after a certain lag time,
but it did not in women. In the case-control study by Yun
and Choi, the effect of ginseng against cancer was relatively
lower in women than in men.6 Since the effect of ginseng in-
take may differ by sex, it needs to be stratified and analyzed
by sex. What causes sex differences in the effect of ginseng
intake has not been clearly explained. Since there are reports
that various ginsenosides and extracts from ginseng influ-
ence cytochrome P450 (CYP) enzyme activity,24,25 sex dif-
ferences in the expression of CYP enzyme in human tissues26
might result in sex differences in the effect of ginseng intake.
This is the first study to examine the association between
ginseng intake and mortality in the general population. The
effect of ginseng intake was assessed through an 18.8-year
prospective study, and almost all subjects were followed up.
When data were collected, trained surveyors visited subjects
to help them prepare the questionnaire instead of sending a
simple questionnaire to them and also measured their height,
weight, and blood pressure directly. Thus the probable in-
formation bias due to self-report was minimized.12,13
There were several limitations to our study. First, infor-
mation on the frequency, duration, and amount of ginseng
intake was not collected in detail. Potential misclassification
might introduce bias measuring the effect of ginseng intake.
Since it was a nondifferential misclassification not related to
deaths, it is possible that any association with mortality was
wrongly concluded to be insignificant. In this study, the re-
lationship of ginseng intake with deaths was not clearly
shown among frequent users, which might have been caused
by the nondifferential misclassification. The case-control
study6,7 and cohort study8 by Yun and Choi and the cohort
study in China9,10 were all conducted later than the Kang-
wha Cohort Study; in those studies, ginseng intake was ex-
amined in more detail, but outcomes did not include the ef-
fects of intake frequency and intake duration. Meanwhile,
based on the outcome of a cohort study conducted in the
same region as this study,8 we estimated the frequency of
ginseng intake in this study to be 1–11 times per year in in-
frequent users and at least once per month in frequent users.
Second, this study did not collect information on species and
types (eg, red, white, powder, tea) in detail. The difference
in ginsenoside composition among various species of gin-
seng is important in assessing effect and efficacy.27 It has
been suggested that red ginseng may contain the most ac-
tive cancer preventive components.27 But we could not ex-
amine the effect on mortality by species and type of ginseng.
Third, during 18.8 years of follow-up after the initial survey,
subjects were not interviewed about how ginseng intake and
other potential confounders had changed. As their physical
conditions or other factors had evolved, the pattern of gin-
seng intake and confounders might have changed. Fourth,
in this study, ginseng intake lowered the risk of all-cause
deaths in men, while its preventive effect on deaths was
weak. Residual confounding by unmeasured variables or
measurement error may be the reason. Fifth, only a small
number of studies have examined the preventive effect of
ginseng intake on mortality and thus much stronger evi-
dence is required to confirm any effects.28 Therefore, read-
ers of this report should be careful to understand this study.
In conclusion, this progressive cohort study over 18.8
years showed that ginseng intake decreased all-cause mor-
tality in elderly males, but no similar effect was found in
women. Cardiovascular disease deaths and ginseng intake
were not related in both men and women. In women gin-
seng intake decreased cancer mortality risk, but insignifi-
cantly.
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